Phase III trial beginning for a Charcot-Marie-Tooth disease therapy
An investigational therapy for Charcot-Marie-Tooth (CMT) disease is beginning its second Phase III trial. The therapy, called PXT3003, is...
An investigational therapy for Charcot-Marie-Tooth (CMT) disease is beginning its second Phase III trial. The therapy, called PXT3003, is...
Blood tests make diagnosis easier, but blood test and biomarkers for traumatic brain injury have historically been lacking. Now,...
Aspirin, one of the most widely used drugs for a variety of indications has been the mainstay of analgesic/anti-inflammatory...
Congenital anomalies, also known as birth defects are among the leading causes of mortality in children less than five...
Breast cancer remains to be the most common malignancy in women and places second on the causes of morbidity...
According to the World Health Organization (WHO), it is estimated that 1 out of 700 newborn babies are born...
Six months after the COVID-19 outbreak, with more than 10 million cases and 500,000 deaths worldwide, the end of...
The SARS-CoV2, a novel coronavirus causing the COVID-19, has already infected more than five million people in the entire...
On December 31, 2019, a cluster of cases with pneumonia of unknown cause was detected in Wuhan, China. Later...
How morbid are comorbidities: COVID-19 comorbidities and how they affect prognosis COVID-19 would give an individual a critical state when...